Pozen MT 100 Indication For Migraine Without Nausea To Be Considered By Committee
This article was originally published in The Pink Sheet Daily
FDA's Peripheral & Central Nervous System Drugs Advisory Committee will weigh whether Pozen should go forward with additional study in non-nauseated migraine patients.
You may also be interested in...
FDA's Peripheral & Central Nervous System Drugs Advisory Committee says additional studies of the naproxen/metoclopramide product must show an effect on two-hour pain-free response.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.